Related Experiment Video

Updated: Nov 26, 2025

Optimization of a Quantitative Micro-neutralization Assay
10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

21.6K

Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19

Satoru Chiba1

  • 1Department of Internal Medicine, Sapporo Suzuki Hospital, 1-27, Shinkotoni-3jo-1chome, 001-0903, Kita-ku, Sapporo, Hokkaido, Japan. chibas_0317@yahoo.co.jp.

Wiener Klinische Wochenschrift
|December 9, 2020
PubMed

Insights

Early oseltamivir treatment for suspected COVID-19 patients without hypoxia reduced fever duration. This antiviral, combined with antibiotics, showed effectiveness in outpatient settings.

Area of Science:

  • Infectious Diseases
  • Virology
  • Public Health

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, has led to global health challenges since late 2019.
  • Investigating effective treatments for COVID-19, particularly in non-hypoxic outpatients, is crucial.

Purpose of the Study:

  • To evaluate the effectiveness of oseltamivir in treating COVID-19 suspected outpatients without hypoxia.
  • To compare early versus late initiation of oseltamivir treatment.

Main Methods:

  • A study involving 16 medical personnel and their families suspected of COVID-19 without hypoxia.
  • Patients received a combination of antiviral (oseltamivir) and antibacterial therapy.
  • Comparison between early treatment (ET) initiated within 24 hours and late treatment (LT) initiated after 24 hours.

Main Results:

  • The study included 10 females (63%), with one patient having diabetes and three with hypertension.
  • Early oseltamivir administration (ET) resulted in a significantly shorter fever duration (31 ± 21 hours) compared to late administration (LT) (94 ± 38 hours).
  • Fever duration correlated with the time from fever onset to treatment initiation and the time from peak to decline.

Conclusions:

  • Early oseltamivir administration, in conjunction with antibacterial therapy, appears to reduce fever duration in COVID-19 suspected outpatients without hypoxia.
  • Prompt treatment initiation is associated with better outcomes regarding fever resolution.
Abstract

Keywords:
Antiviral agentsCOVID-19Duration of feverEarly treatmentLevofloxacin

More Related Videos

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

18.8K
A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects05:46

A Novel Inhalation Mask System to Deliver High Concentrations of Nitric Oxide Gas in Spontaneously Breathing Subjects

Published on: May 4, 2021

5.5K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
441
Respiratory Assessment: Purpose and Indications01:19

Respiratory Assessment: Purpose and Indications

Respiratory assessment is a cornerstone of nursing assessments, crucial for the early detection of patient deterioration. This evaluation transcends routine procedures, representing a critical skill nurses must master to ensure optimal patient care.
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
1.4K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
307
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
596
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
557
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
785